Arena's US$608 M GPCR collaboration agreement with Ortho-McNeil is one of the highest value preclinical deals in biotech's history. Here we analyse the diabetes collaboration, looking at why it was valued so highly and why the alliance may turn out to be broader than it appears on the surface.